000118667 001__ 118667
000118667 005__ 20240319081023.0
000118667 0247_ $$2doi$$a10.3390/antibiotics11050698
000118667 0248_ $$2sideral$$a129656
000118667 037__ $$aART-2022-129656
000118667 041__ $$aeng
000118667 100__ $$aAriño Pérez, I.
000118667 245__ $$aManagement of Helicobacter Pylori infection and effectiveness rates in daily clinical practice in Spain: 2010–2019
000118667 260__ $$c2022
000118667 5060_ $$aAccess copy available to the general public$$fUnrestricted
000118667 5203_ $$aThe management and effectiveness of the treatment of Helicobacter pylori infection are heterogeneous worldwide, despite the publication of international consensus conferences and guidelines, which have been widely available for years. The aim of the study was to describe the clinical management and the eradication rates in a region of Southern Europe (Spain). Between 2010 and 2019, we conducted a retrospective analysis of patients with H. pylori infection attended by gastroenterologists in two defined areas of the National Health System in Aragón. We compared the appropriateness of therapies according to guidelines, and described the effectiveness of each treatment. A total of 1644 penicillin non-allergic patients were included. The most prescribed therapy between 2010 and 2013 was the ‘classic’ triple therapy PCA (80%), whereas the ’concomitant’ therapy PCAM was chosen by 90% of the gastroenterologists in 2015. After 2016, the use of the quadruple bismuth-containing therapy in a single capsule (Pylera®) quickly increased, representing almost half of the overall prescriptions in 2019. Throughout the decade, adherence to guidelines was 76.4% and global efficacy was 70.7% (ITT). Triple therapies’ eradication rates were lower than 70% (ITT), whereas eradication rates with quadruple therapies achieved or were over 80% (ITT). In conclusion, despite the use of quadruple therapies and optimized treatments, the effectiveness of H. pylori management in daily clinical practice is far from the target of 90%.
000118667 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000118667 590__ $$a4.8$$b2022
000118667 592__ $$a0.792$$b2022
000118667 591__ $$aPHARMACOLOGY & PHARMACY$$b65 / 278 = 0.234$$c2022$$dQ1$$eT1
000118667 593__ $$aPharmacology, Toxicology and Pharmaceutics (miscellaneous)$$c2022$$dQ1
000118667 591__ $$aINFECTIOUS DISEASES$$b35 / 96 = 0.365$$c2022$$dQ2$$eT2
000118667 593__ $$aInfectious Diseases$$c2022$$dQ2
000118667 593__ $$aMicrobiology (medical)$$c2022$$dQ2
000118667 593__ $$aPharmacology (medical)$$c2022$$dQ2
000118667 593__ $$aBiochemistry$$c2022$$dQ2
000118667 593__ $$aMicrobiology$$c2022$$dQ2
000118667 594__ $$a5.5$$b2022
000118667 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000118667 700__ $$aMartínez Domínguez, S. J.
000118667 700__ $$aAlfaro Almajano, E.$$uUniversidad de Zaragoza
000118667 700__ $$aCarrera Lasfuentes, P.
000118667 700__ $$0(orcid)0000-0001-5932-2889$$aLanas, Á.$$uUniversidad de Zaragoza
000118667 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000118667 773__ $$g11, 5 (2022), 698 [13 pp.]$$pAntibiotics$$tAntibiotics$$x2079-6382
000118667 8564_ $$s1298242$$uhttps://zaguan.unizar.es/record/118667/files/texto_completo.pdf$$yVersión publicada
000118667 8564_ $$s2836127$$uhttps://zaguan.unizar.es/record/118667/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000118667 909CO $$ooai:zaguan.unizar.es:118667$$particulos$$pdriver
000118667 951__ $$a2024-03-18-16:26:34
000118667 980__ $$aARTICLE